In an amazing update for the ALS community, on September 29, 2022, the FDA voted to approve ALS drug AMX0035 for the treatment of ALS. This comes a year after Amylyx, a Massachusetts-based pharmaceutical company, submitted a New Drug Application (NDA) for AMX0035, a...
One month ago on May 25, 2021, representatives from the FDA joined a We Can’t Wait Action Meeting. During this meeting, eight ALS advocates from across the US shared their personal experience with the disease to highlight why those with ALS need expedited access to...
The average life expectancy for someone after an ALS diagnosis is only 2 – 5 years. However, the process of developing, testing, and approving new treatments takes far longer. For those living with ALS, time is limited—We Can’t Wait. On May 25, 2021, representatives...
Based on information as of 5/5/2017 What is Radicava? Radicava™ (edaravone) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) to treat people with amyotrophic lateral sclerosis (ALS).1 In clinical trials, some people given Radicava...
Radicava is First Approved Treatment for ALS in Decades The Food and Drug Administration’s (FDA) announced today that it has approved Radicava (edaravone), the first new treatment approved specifically for ALS in 22 years. The FDA approved Radicava less than a year...
